Rasmus Sørrig

1.2k total citations · 1 hit paper
19 papers, 777 citations indexed

About

Rasmus Sørrig is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Oncology. According to data from OpenAlex, Rasmus Sørrig has authored 19 papers receiving a total of 777 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 12 papers in Endocrinology, Diabetes and Metabolism and 5 papers in Oncology. Recurrent topics in Rasmus Sørrig's work include Diabetes Treatment and Management (12 papers), Metabolism, Diabetes, and Cancer (11 papers) and Multiple Myeloma Research and Treatments (5 papers). Rasmus Sørrig is often cited by papers focused on Diabetes Treatment and Management (12 papers), Metabolism, Diabetes, and Cancer (11 papers) and Multiple Myeloma Research and Treatments (5 papers). Rasmus Sørrig collaborates with scholars based in Denmark, United States and United Kingdom. Rasmus Sørrig's co-authors include Ole Kleist Jeppesen, Dan Hesse, Silva Arslanian, Aaron S. Kelly, Daniel Weghuber, Inge Gies, Timothy Barrett, Margarita Barrientos‐Pérez, Lucy D. Mastrandrea and Marianne Bach Treppendahl and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and Diabetes Care.

In The Last Decade

Rasmus Sørrig

18 papers receiving 767 citations

Hit Papers

Once-Weekly Semaglutide in Adolescents with Obesity 2022 2026 2023 2024 2022 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Once-Weekly Semaglutide in Adolescents with Obesity
    2022 338 citations Daniel Weghuber, Timothy Barrett et al. New England Journal of Medicine profile →

Peers

Rasmus Sørrig
Jon Rasmussen Denmark
Veronica Resi Italy
Oswaldo L. Bracco United States
Annalisa Giandalia Italy
Mary Seger United States
Olga Montvida Australia
Maria Faria Portugal
Robert Boggs United States
Eleanor Elstein Canada
Jon Rasmussen Denmark
Rasmus Sørrig
Citations per year, relative to Rasmus Sørrig Rasmus Sørrig (= 1×) peers Jon Rasmussen

Countries citing papers authored by Rasmus Sørrig

Since Specialization
Citations

This map shows the geographic impact of Rasmus Sørrig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rasmus Sørrig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rasmus Sørrig more than expected).

Fields of papers citing papers by Rasmus Sørrig

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rasmus Sørrig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rasmus Sørrig. The network helps show where Rasmus Sørrig may publish in the future.

Co-authorship network of co-authors of Rasmus Sørrig

This figure shows the co-authorship network connecting the top 25 collaborators of Rasmus Sørrig. A scholar is included among the top collaborators of Rasmus Sørrig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rasmus Sørrig. Rasmus Sørrig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Verma, Subodh, Morten Bøttcher, Paul Brown, et al.. (2025). CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1. Hypertension. 83(2). e26055–e26055. 1 indexed citations
2.
Heerspink, Hiddo J.L., Melanie J. Davies, Dror Dicker, et al.. (2023). Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials. Diabetes Care. 46(4). 801–810. 63 indexed citations
3.
Kelly, Aaron S., Silva Arslanian, Dan Hesse, et al.. (2023). Reducing BMI below the obesity threshold in adolescents treated with once‐weekly subcutaneous semaglutide 2.4 mg. Obesity. 31(8). 2139–2149. 24 indexed citations
4.
Horn, Deborah B., Domenica Rubino, Rasmus Sørrig, et al.. (2023). A model‐based approach to predict individual weight loss with semaglutide in people with overweight or obesity. Diabetes Obesity and Metabolism. 25(11). 3171–3180. 18 indexed citations
5.
Kabir, Ali, Daniel Weghuber, Timothy Barrett, et al.. (2023). ONCE-WEEKLY SUBCUTANEOUS SEMAGLUTIDE 2.4 MG IN ADOLESCENTS WITH OVERWEIGHT OR OBESITY. Canadian Journal of Diabetes. 47(7). S181–S182.
6.
Weghuber, Daniel, Timothy Barrett, Margarita Barrientos‐Pérez, et al.. (2023). Once-weekly semaglutide in adolescents with obesity. Yearbook of pediatric endocrinology. 1 indexed citations
7.
Weghuber, Daniel, Timothy Barrett, Margarita Barrientos‐Pérez, et al.. (2022). Once-Weekly Semaglutide in Adolescents with Obesity. New England Journal of Medicine. 387(24). 2245–2257. 338 indexed citations breakdown →
8.
Heerspink, Hiddo J.L., Melanie J. Davies, Dror Dicker, et al.. (2022). POS-336 SEMAGLUTIDE 2.4 MG AND 1.0 MG IMPROVED ALBUMINURIA IN ADULTS WITH OVERWEIGHT/OBESITY AND TYPE 2 DIABETES IN STEP 2. Kidney International Reports. 7(2). S152–S153. 2 indexed citations
9.
Hesse, Dan, et al.. (2022). Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study. Journal of Comparative Effectiveness Research. 12(2). e220187–e220187. 7 indexed citations
10.
Aroda, Vanita R., Robert Bauer, CHRISTIN L. HERTZ, et al.. (2020). 932-P: Efficacy and Safety of Oral Semaglutide by Baseline Age in the PIONEER Clinical Trial Program. Diabetes. 69(Supplement_1). 7 indexed citations
11.
Desouza, Cyrus, Aslam Amod, Klaus Kallenbach, et al.. (2020). 930-P: Efficacy of Oral Semaglutide According to Race: An Exploratory Subgroup Analysis of the PIONEER Trial Program. Diabetes. 69(Supplement_1). 4 indexed citations
12.
Dungan, Kathleen, CHRISTIN L. HERTZ, Linda Mellbin, et al.. (2020). 964-P: Glycemic and Body Weight Responses to Oral Semaglutide in the PIONEER Trial Program. Diabetes. 69(Supplement_1). 2 indexed citations
13.
Andersen, Michael Asger, Carsten Utoft Niemann, Klaus Rostgaard, et al.. (2020). Differences and Temporal Changes in Risk of Invasive Pneumococcal Disease in Adults with Hematological Malignancies: Results from a Nationwide 16-Year Cohort Study. Clinical Infectious Diseases. 72(3). 463–471. 28 indexed citations
14.
Husain, Mansoor, Stephen C. Bain, Ole Kleist Jeppesen, et al.. (2020). Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obesity and Metabolism. 22(3). 442–451. 145 indexed citations
15.
Sørrig, Rasmus, Tobias Wirenfeldt Klausen, Birgitte Preiss, et al.. (2018). Early relapsed disease of multiple myeloma following up-front HDM-ASCT: a study based on the Danish Multiple Myeloma Registry in the period 2005 to 2014. Leukemia. 32(9). 2054–2057. 7 indexed citations
16.
Sørrig, Rasmus, Tobias Wirenfeldt Klausen, Morten Salomo, Annette Juul Vangsted, & Peter Gimsing. (2018). Risk factors for blood stream infections in multiple myeloma: A population‐based study of 1154 patients in Denmark. European Journal Of Haematology. 101(1). 21–27. 22 indexed citations
17.
Sørrig, Rasmus, Tobias Wirenfeldt Klausen, Morten Salomo, Annette Juul Vangsted, & Peter Gimsing. (2018). Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study. European Journal Of Haematology. 102(2). 182–190. 26 indexed citations
18.
Sørrig, Rasmus, Tobias Wirenfeldt Klausen, Morten Salomo, et al.. (2017). Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population. PLoS ONE. 12(12). e0188988–e0188988. 37 indexed citations
19.
Sørrig, Rasmus, Tobias Wirenfeldt Klausen, Morten Salomo, et al.. (2015). Smoldering multiple myeloma risk factors for progression: a Danish population‐based cohort study. European Journal Of Haematology. 97(3). 303–309. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jon Rasmussen Breakdown of academic impact, for papers by Veronica Resi Breakdown of academic impact, for papers by Oswaldo L. Bracco Breakdown of academic impact, for papers by Annalisa Giandalia Breakdown of academic impact, for papers by Mary Seger Breakdown of academic impact, for papers by Olga Montvida Breakdown of academic impact, for papers by Maria Faria Breakdown of academic impact, for papers by Robert Boggs Breakdown of academic impact, for papers by Eleanor Elstein
Rankless by CCL
2026